Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
- Associated Therapies
- -
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
- Conditions
- Interventions
- Drug: CyclophosphamideDrug: ClofarabineDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DasatinibDrug: DexamethasoneOther: Laboratory Biomarker AnalysisDrug: Doxorubicin HydrochlorideDrug: EtoposideDrug: Hydrocortisone Sodium SuccinateDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseRadiation: Radiation TherapyDrug: PrednisoneDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5949
- Registration Number
- NCT02883049
- Locations
- 🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
Optimization of Therapy in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
- Conditions
- Interventions
- Drug: RituximabProcedure: Cranial irradiationDrug: NelarabineDrug: IdarubicinDrug: PEG-AsparaginaseDrug: ImatinibDrug: FludarabineDrug: DexamethasoneDrug: CyclophosphamideDrug: VincristineDrug: MethotrexateProcedure: Stem cell transplantationDrug: MercaptopurineDrug: CytarabineDrug: VP16Drug: VindesineDrug: Daunorubicin (DNR)Drug: AdriamycinDrug: Prednisolone
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 1000
- Registration Number
- NCT02881086
- Locations
- 🇩🇪
University Hospital of Frankfurt (Main), Frankfurt (Main), Germany
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Biological: BlinatumomabDrug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneDrug: Doxorubicin HydrochlorideBiological: Inotuzumab OzogamicinOther: Laboratory Biomarker AnalysisDrug: MercaptopurineDrug: MethotrexateBiological: OfatumumabDrug: PrednisoneBiological: RituximabDrug: Vincristine Sulfate
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT02877303
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
- Conditions
- Interventions
- Drug: AzacitidineDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Hydrocortisone Sodium SuccinateOther: Laboratory Biomarker AnalysisDrug: LeucovorinDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseOther: Pharmacological StudyDrug: PrednisoloneDrug: ThioguanineDrug: VincristineDrug: Vincristine Sulfate
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT02828358
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT02776605
- Locations
- 🇪🇸
Hospital Clinic, Barcelona, Spain
🇪🇸Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸Hospital 12 de Octubre, Madrid, Spain
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 171
- Registration Number
- NCT02723994
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Texas Childrens Hospital, Houston, Texas, United States
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 280
- Registration Number
- NCT02688140
- Locations
- 🇩🇪
OSHO study group, Multiple Locations, Germany
🇩🇪SAL study group, Multiple Locations, Germany
🇳🇱HOVON study group, Multiple Locations, Netherlands
Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL
- Conditions
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 100
- Registration Number
- NCT02660762
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
- Conditions
- Interventions
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT02553460
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Rady Children's Hospital and Health Center, San Diego, California, United States
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: DasatinibDrug: prednisoneDrug: cyclophosphamideDrug: daunorubicinDrug: vincristineDrug: cytarabineDrug: mercaptopurineDrug: methotrexateDrug: dexamethasoneDrug: mitoxantroneDrug: etoposideProcedure: allogeneic hematopoietic stem cell transplantationProcedure: autologous hematopoietic stem cell transplantation
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2022-08-03
- Target Recruit Count
- 30
- Registration Number
- NCT02523976
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.